Get the Stockscreener App
21.85
2.15%
0.46
After Hours:
21.85
Overview
News
Price History
Option Chain
Financials
Why KVUE Down?
Discussions
Forecast
Dividend History
Kenvue Inc stock is traded at $21.85, with a volume of 21.50M.
It is up +2.15% in the last 24 hours and up +0.92% over the past month.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
See More
Previous Close:
$21.39
Open:
$21.31
24h Volume:
21.50M
Relative Volume:
1.09
Market Cap:
$41.92B
Revenue:
$15.30B
Net Income/Loss:
$1.06B
P/E Ratio:
39.73
EPS:
0.55
Net Cash Flow:
$1.45B
1W Performance:
+5.25%
1M Performance:
+0.92%
6M Performance:
+3.11%
1Y Performance:
+19.73%
1-Day Range:
$21.29
$21.92
1-Week Range:
$20.64
$22.59
52-Week Range:
$17.85
$25.17
Kenvue Inc Stock (KVUE) Company Profile
Name
Kenvue Inc
Sector
Industry
Phone
908-874-1200
Address
1 KENVUE WAY, SUMMIT
Compare KVUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KVUE
Kenvue Inc
|
21.85 | 39.86B | 15.30B | 1.06B | 1.45B | 0.55 |
|
PG
Procter Gamble Co
|
153.73 | 369.31B | 83.93B | 15.50B | 15.03B | 6.30 |
|
UL
Unilever Plc Adr
|
60.32 | 149.07B | 65.10B | 6.16B | 0 | 2.4569 |
|
CL
Colgate Palmolive Co
|
87.66 | 74.22B | 19.95B | 2.90B | 3.47B | 3.54 |
|
KMB
Kimberly Clark Corp
|
127.63 | 43.63B | 19.75B | 2.47B | 2.39B | 7.34 |
Kenvue Inc Stock (KVUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Redburn Atlantic | Neutral |
| Mar-24-25 | Initiated | Evercore ISI | In-line |
| Jan-06-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-12-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-24-24 | Initiated | Jefferies | Buy |
| Sep-24-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-28-24 | Resumed | Citigroup | Neutral |
| Apr-11-24 | Initiated | Bernstein | Underperform |
| Apr-03-24 | Initiated | William Blair | Mkt Perform |
| Mar-01-24 | Resumed | Goldman | Neutral |
| Nov-17-23 | Initiated | Piper Sandler | Neutral |
| Sep-11-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-07-23 | Initiated | Canaccord Genuity | Buy |
| Sep-06-23 | Initiated | Argus | Hold |
| Aug-24-23 | Upgrade | Goldman | Neutral → Buy |
| Jul-25-23 | Initiated | Edward Jones | Buy |
| Jun-01-23 | Initiated | HSBC Securities | Hold |
| May-30-23 | Initiated | BofA Securities | Buy |
| May-30-23 | Initiated | Citigroup | Neutral |
| May-30-23 | Initiated | Deutsche Bank | Hold |
| May-30-23 | Initiated | Exane BNP Paribas | Neutral |
| May-30-23 | Initiated | Goldman | Neutral |
| May-30-23 | Initiated | JP Morgan | Overweight |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Initiated | UBS | Neutral |
View All
Kenvue Inc Stock (KVUE) Latest News
Tylenol maker Kenvue's CEO quits amid board's strategic review - MSN
Kenvue's Q2 2025 Earnings: What to Expect - MSN
Kenvue's Trading Volume Drops 30% But Stock Rises 215% Ranked 214th in Market - AInvest
Kenvue Stock Has Unusual Put Option Activity After Lower Q2 Sales and CEO Firing - MSN
UBS Keeps Their Hold Rating on Kenvue, Inc. (KVUE) - The Globe and Mail
Kenvue Stock Has Unusual Put Option Activity After Lower Q2 Sales And CEO Firing - Barchart.com
Legacy Capital Wealth Partners LLC Reduces Position in Kenvue Inc. (NYSE:KVUE) - MarketBeat
Equity Investment Corp Sells 893,724 Shares of Kenvue Inc. (NYSE:KVUE) - MarketBeat
Kenvue CEO Thibaut Mongon departs - Storyboard18
Tylenol maker Kenvue fires CEO amid board's strategic review - MSN
Kenvue Initiates CEO Transition and Strategic Review to Drive Shareholder Value - Global Cosmetics News
Drystone LLC Purchases 58,267 Shares of Kenvue Inc. (NYSE:KVUE) - MarketBeat
Kenvue Stock Plummets 48.15% in Trading Volume Ranking 148th - AInvest
M&T Bank Corp Has $2.83 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE) - MarketBeat
Kenvue (NYSE:KVUE) Price Target Cut to $22.00 by Analysts at Citigroup - MarketBeat
Barclays Lowers Kenvue (NYSE:KVUE) Price Target to $22.00 - MarketBeat
Tylenol maker Kenvue ousts CEO amid board's strategic review - MSN
Kenvue Inc. (NYSE:KVUE) Shares Bought by Arizona State Retirement System - MarketBeat
Kenvue Inc. (KVUE) Has “Good Brands,” Says Jim Cramer - MSN
Kenvue's Q2 2025 Earnings: What To Expect - Barchart.com
Kenvue Inc. (KVUE) Has "Good Brands," Says Jim Cramer - Yahoo Finance
Kenvue: B of A Securities maintains a 'Buy' Rating, The Target Price is $25 - AInvest
Citi lowers Kenvue stock price target to $22 on CEO transition concerns - Investing.com Canada
Kenvue stock rises as UBS maintains Neutral rating amid CEO change - Investing.com India
Bank of America Cuts Kenvue (NYSE:KVUE) Price Target to $25.00 - MarketBeat
Strategic Shifts and Leadership Changes Position Kenvue, Inc. for Growth: A Buy Rating Justification - TipRanks
Kenvue's Crossroads: Can New Leadership Sustain Dividends Through Strategic Overhaul? - AInvest
Kenvue: New CEO, Watch The Dividend (Rating Downgrade) (NYSE:KVUE) - Seeking Alpha
Kenvue price target lowered to $22 from $23 at Barclays - TipRanks
Kenvue Announces CEO Transition and Strategic Review - The Globe and Mail
Kenvue price target lowered to $25 from $27 at BofA - TipRanks
Kenvue, Inc. Buy Rating Reiterated Amid CEO Transition and Strategic Review - TipRanks
Mutual of America Capital Management LLC Sells 55,866 Shares of Kenvue Inc. (NYSE:KVUE) - MarketBeat
Want to Generate at Least $1,000 in Passive Income Per Year? Invest $26,000 in This Dividend King Stock. - AOL.com
Want to Generate at Least $1,000 in Passive Income Per Year? Invest $26,000 in This Dividend King Stock. - The Motley Fool
Greenleaf Trust Buys New Position in Kenvue Inc. (NYSE:KVUE) - MarketBeat
Domino's Sets Sights On Faster US Sales While Starbucks Tightens Office Rules - Finimize
Kenvue Makes CEO Change Months After Critical Activist Investor Made Proxy Play For Board Seat - insights.citeline.com
Kenvue's Trading Volume Surges 130.82% to 12.73 Billion, Ranks 57th in Market - AInvest
Health Care Ticks Down as Merger Activity Offsets Health-Insurance RoutHealth Care Roundup - MarketScreener
Kenvue names interim CEO, launches strategic review - FashionNetwork USA
Kirk Perry Appointed Interim CEO of Kenvue Amid Strategic Review - WWD
Tylenol-Maker Kenvue Launches Turnaround Plans. How Should You Play KVUE Stock Here? - MSN
Kenvue CEO ousted, company announces strategic review - Yahoo Finance
Kenvue's CEO Search and SHB Review Raise Questions, but Core Brands Still Show Stability - Morningstar
Kenvue Surges After Tylenol-Maker Announces Sweeping Changes - MSN
Kenvue Sees Unusually Large Options Volume (NYSE:KVUE) - MarketBeat
Kenvue Makes CEO Change and Acts to Unlock Shareholder Value - New Jersey Business Magazine
Kenvue (NYSE:KVUE) Appoints Kirk Perry As Interim CEO For Transformation Initiative - Yahoo Finance
Kenvue Names Interim CEO, Explores Strategic Options - AInvest
Kenvue (NYSE:KVUE) Shares Gap UpStill a Buy? - MarketBeat
Kenvue Inc Stock (KVUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):